EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Adverse events following immunization during COVID-19 mass vaccination campaigns in the Democratic Republic of Congo: Findings from active safety surveillance

Kizito Kayumba iD, Alemayehu Duga, Mosoka Papa Fallah, Claire Tshidibi, Nicky Lubaki, Barnabas Coulibaly, Benjamin Djoudalbaye, Efire Nora Sylvana, Senga Lucy Sembuche, Tedi Tilahun, Murtala Jibril, Carlos Kilowe und 6 weitere

PLOS One · 10.07.2026 · 21 (7) · e0309628

DOI: 10.1371/journal.pone.0309628 ↗

Kurz gefasst

Fachartikel in der Zeitschrift PLOS One, online erschienen am 10.07.2026. Verfasst von Kizito Kayumba und 17 weiteren Autor:innen. Beteiligte Einrichtung: Africa Centres for Disease Control and Prevention (Africa CDC), Addis Ababa, Ethiopia. Hauptthemen laut MEDLINE: Mass Vaccination, COVID-19 Vaccines, COVID-19. Die Arbeit nennt 24 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Mastercard Foundation.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Introduction

Post-marketing safety surveillance is essential for ensuring vaccine safety and maintaining public trust, particularly in African settings where evidence on the safety of COVID–19 vaccines remains limited. This study aimed to determine the overall incidence and types of AEFIs, as well as the factors associated with their occurrence, during COVI-19 mass vaccination campaigns in Democratic Republic of Congo.

Methods

From December 1–29, 2023, a prospective safety surveillance study was conducted in Kinshasa Province. Participants were surveyed through phone calls from day 1–28 following COVID-19 vaccine administration. AEFI incidence rates were calculated by type of vaccine, sex, number of dose and age group. Factors associated with AEFIs were identified using multivariable logistic regression models, expressed by adjusted odds ratio and its 95% confidence interval.

Results

The study included 4766 participants. Their median [IQR] age was 36 [27−48] years and 2503 (53%) were males, 94.63% received the J&J vaccine while 256 (5.37%) received the BNT162b2 vaccine. Incidence of AEFIs was 23.75% (95%CI: 22.54%−24.99%). AEFIs mostly reported were fever (9.61%, 95%CI: 8.88%−10.48%), injection site pain (9.00%, 95%CI: 8.20%−9.85%), headache (4.11%, 95%CI: 3.57%−4.72%), stiffness (1.51%, 95%CI: 1.18%−1.89%) and myalgia (1.15%, 95%CI: 0.87%−1.49%). The incidence of AEFIs was higher for the BNT162b2 vaccine at 34.48% (95% CI: 28.57%−40.54%) vs. 23.15% (95% CI: 21.92%−24.41%) for the J&J vaccine. Compared to participants aged 18−59 years, those under 18 years old were associated with decreased odds of reporting any AEFI (aOR= 0.26, 95%CI: 0.13–0.88) and injection site pain (aOR=0.18, 95%CI: 0.05–0.75). Those aged 60 years and older were associated with decreased odds of reporting any AEFI (aOR= 0.78, 95%CI: 0.62–0.99) and fever (aOR=0. 63, 95%CI: 0.43–0.92).

Conclusions

Approximately one-quarter of participants reported AEFI. The observed association with vaccine type and age underscores the need for systematic vaccine safety monitoring in the population. This is critical for guiding future vaccination strategies tailored to individuals who may be more susceptible to AEFIs.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Mass VaccinationCOVID-19 VaccinesCOVID-19HumansMaleDemocratic Republic of the CongoFemaleAdultMiddle AgedIncidenceProspective StudiesBNT162 VaccineAdolescentSARS-CoV-2

Substanzen

COVID-19 VaccinesBNT162 Vaccine

Autor:innen und Institutionen

  • Africa Centres for Disease Control and Prevention (Africa CDC), Addis Ababa, Ethiopia.
  • Ministry of Health, Kinshasa, Democratic Republic of Congo.

ORCID-Profile: Kizito Kayumba, Nicaise Ndembi

Förderung

  • Mastercard Foundation

Zitieren

APA

Kayumba, K., Duga, A., Papa Fallah, M., Tshidibi, C., Lubaki, N., Coulibaly, B., Djoudalbaye, B., Nora Sylvana, E., Sembuche, S. L., Tilahun, T., Jibril, M., Kilowe, C., Kuba, A., Mafwila Lusala, A., Dereje, N., Ndembi, N., Raji, T., & Ngongo, N. (2026). Adverse events following immunization during COVID-19 mass vaccination campaigns in the Democratic Republic of Congo: Findings from active safety surveillance. PLOS One, 21(7), e0309628. https://doi.org/10.1371/journal.pone.0309628

Vancouver

Kayumba K, Duga A, Papa Fallah M, Tshidibi C, Lubaki N, Coulibaly B, et al. Adverse events following immunization during COVID-19 mass vaccination campaigns in the Democratic Republic of Congo: Findings from active safety surveillance. PLOS One. 2026;21(7):e0309628. doi:10.1371/journal.pone.0309628

BibTeX
@article{Kayumba2026,
  author = {Kayumba, Kizito and Duga, Alemayehu and Papa Fallah, Mosoka and Tshidibi, Claire and Lubaki, Nicky and Coulibaly, Barnabas and Djoudalbaye, Benjamin and Nora Sylvana, Efire and Sembuche, Senga Lucy and Tilahun, Tedi and Jibril, Murtala and Kilowe, Carlos and Kuba, Aminu and Mafwila Lusala, Antoine and Dereje, Nebiyu and Ndembi, Nicaise and Raji, Tajudeen and Ngongo, Ngashi},
  title = {Adverse events following immunization during COVID-19 mass vaccination campaigns in the Democratic Republic of Congo: Findings from active safety surveillance},
  journal = {PLOS One},
  year = {2026},
  volume = {21},
  number = {7},
  pages = {e0309628},
  doi = {10.1371/journal.pone.0309628}
}
Kostenlos starten →